A Master Protocol for a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of REGN9933 and REGN7508, Monoclonal Antibodies Against Factor XI for Prevention of Venous Thromboembolism in Patients With a Peripherally Inserted Central Catheter (ROXI-CATH)
Latest Information Update: 30 Jun 2025
At a glance
Most Recent Events
- 24 Jun 2025 Planned End Date changed from 29 Jun 2026 to 8 Jun 2026.
- 24 Jun 2025 Planned primary completion date changed from 29 Jun 2026 to 8 Jun 2026.
- 01 Oct 2024 Planned End Date changed from 7 Jul 2026 to 29 Jun 2026.